Logo

Incyte and Novartis Relationship to Include Microarray Technology

Dec 18, 1998
Premium

PALO ALTO, Calif.--Incyte Pharmaceuticals announced that it has expanded its relationship with Novartis Pharma to include access to Incyte's gene expression microarray technology. The four-year agreement provides Novartis with data from pre-fabricated DNA microarrays and data from custom microarrays in exchange for access fees and per-experiment fees. Novartis will also gain access to Incyte's GEMTools software to manage and analyze the data.

Filed under

Informatics
Breaking News
The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.